Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 5 examiners • 0 of 7 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The University of Leicester currently manages 8 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 5 distinct art units, indicating a diverse range of subject matter within the life sciences sector. The prosecution work involves 6 distinct examiners, suggesting that the university interacts with a variety of examination styles and preferences across its active applications.
SKELDING, ZACHARY S serves as the busiest examiner for this portfolio, currently handling 3 pending office actions. This concentration with a single examiner represents a significant portion of the 8 total pending actions. Practitioners should note that while the portfolio spans 5 distinct art units, a concentration of the active workload is centralized under a single individual, which may impact overall prosecution timelines and consistency. The involvement of 6 distinct examiners across the various units suggests that most examiners are working within their own specialized groups.
Managing the workload requires a coordinated approach to address the specific requirements of the Biotechnology & Pharmaceuticals field. With 3 pending office actions assigned to SKELDING, ZACHARY S, the university's strategy may be heavily influenced by the feedback and precedents set by this specific examiner. The remaining actions are spread among the other distinct examiners, providing a broader base of examiner interactions that could help mitigate the risks associated with any single examiner's tendencies.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §103 only | 2 (29%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 3 | 59.7% | +41.2% |
| WANG, CHANG YU | 1 | 33.5% | +53.5% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.3% | +49.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18355871 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | SKELDING, ZACHARY S | 69d |
| 18290241 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | JOHNSON, CHRISTOPHER LINDSAY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18355871 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | SKELDING, ZACHARY S | 69d |
| 17498521 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria | STONEBRAKER, ALYSSA RAE | 76d |
| 18633379 | METHODS FOR INHIBITING ANGIOGENESIS IN A SUBJECT IN NEED THEREOF | WANG, CHANG YU | — |
| 18290241 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18474631 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | — |
| 18312891 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | — |
| 18051993 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | BENAVIDES, JENNIFER ANN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1691 | 1 |
| 1675 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18633379 | METHODS FOR INHIBITING ANGIOGENESIS IN A SUBJECT IN NEED THEREOF | WANG, CHANG YU | — | §102§112DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18290241 | VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §101§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18474631 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | — | §103 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18355871 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | SKELDING, ZACHARY S | 1644 | §102§103§112 | Non-Final OA | 69d | Pending | Jul 20, 2023 |
| 18312891 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | SKELDING, ZACHARY S | 1644 | §103 | Non-Final OA | — | Pending | May 05, 2023 |
| 18051993 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation | BENAVIDES, JENNIFER ANN | 1675 | §103DP | Final Rejection | — | Pending | Nov 02, 2022 |
| 17498521 | Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria | STONEBRAKER, ALYSSA RAE | 1642 | §112DPOther | Non-Final OA | 76d | Pending | Oct 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial